Get the Stockscreener App
1.90
2.06%
-0.04
After Hours:
2.00
0.10
+5.26%
Acelyrin Inc Stock (SLRN) Latest News
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders - Business Wire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc.SLRN - PR Newswire
Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company -February 06, 2025 at 05:56 pm EST - Marketscreener.com
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders - The Bakersfield Californian
Alumis and ACELYRIN announce merger in all-stock deal By Investing.com - Investing.com South Africa
Alumis and ACELYRIN announce merger in all-stock deal - Investing.com India
Alumis, Acelyrin to merge in all-stock transaction - TipRanks
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - StockTitan
Fenwick Represents ACELYRIN in Pending Merger with Alumis - Fenwick & West LLP
ACELYRIN ends key drug development agreement - MSN
Is Acelyrin Inc (SLRN) a good investment opportunity? - US Post News
ACELYRIN ends key drug development agreement By Investing.com - Investing.com Canada
ACELYRIN, INC. Ends Key Agreement with Affibody - TipRanks
SLRN stock touches 52-week low at $1.9 amid market challenges - MSN
JPMorgan Chase & Co. Cuts Stake in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Barclays PLC Buys 65,188 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin falls after updating mid-stage trial data for eye disease drug - MSN
Acelyrin spikes on upcoming mid-stage data update on eye disease drug - MSN
SLRN Stock Hits 52-Week Low at $2.2 Amid Market Challenges - Investing.com Nigeria
ACELYRIN reports progress in thyroid eye disease treatment By Investing.com - Investing.com Nigeria
Q1 Earnings Forecast for Acelyrin Issued By HC Wainwright - Defense World
HC Wainwright Predicts Acelyrin's Q1 Earnings (NASDAQ:SLRN) - MarketBeat
HC Wainwright Lowers Acelyrin (NASDAQ:SLRN) Price Target to $6.00 - Defense World
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease - Yahoo Finance
Acelyrin To Take Tepezza Competitor Into Phase III In TED - Citeline News & Insights
Citigroup Has Lowered Expectations for Acelyrin (NASDAQ:SLRN) Stock Price - MarketBeat
Citi cuts Acelyrin stock target amid uncertainty in Phase 3 program - Investing.com Canada
Stock market news: ACELYRIN -34.67%, Vuzix -21.58% among biggest losers during mid day trading - Business Upturn
Citi cuts Acelyrin stock target amid uncertainty in Phase 3 program By Investing.com - Investing.com South Africa
Stock market today: Acelyrin -40.40%, Amesite -30.92% among biggest losers in early trading - Business Upturn
Stock market today: XTI Aerospace surged by 108.52% while ACELYRIN posted fall of 38.68% in early trading - Business Upturn
Acelyrin stock falls after TED drug data (SLRN:NASDAQ) - Seeking Alpha
H.C. Wainwright cuts Acelyrin stock target, keeps neutral on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Acelyrin stock target, keeps neutral on trial data - Investing.com
Jane Street Group LLC Decreases Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin stock: Piper Sandler bullish on longigutamab TED treatment potential - Investing.com India
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - The Manila Times
ACELYRIN advances lonigutamab into Phase 3 for TED treatment - Investing.com India
ACELYRIN reports progress in thyroid eye disease treatment - Investing.com
Updated: Acelyrin’s stock drops due to mixed Phase 2 data in thyroid eye disease - Endpoints News
Acelyrin announces additional lonigutamab data, design for LONGITUDE program - TipRanks
Acelyrin (SLRN) Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - StreetInsider.com
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in - The Bakersfield Californian
ACELYRIN's Thyroid Eye Disease Drug Shows Promise in Phase 2, Advances to Pivotal Trials - StockTitan
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 - MSN
AEON Biopharma announces share offering - MSN
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):